October is Breast Cancer Awareness Month, a time to reflect on the progress made and the work still ahead in the fight against one of the most prevalent and costly cancers affecting predominantly women. For Prime Therapeutics (Prime), it’s also a moment to spotlight the company’s commitment to clinical innovation, strategic partnerships and most importantly, member-first oncology care. 

At Prime’s annual Specialty Summit in New York City, Abby Kim, PharmD, BCOP, oncology pharmacist, senior principal for Prime, joined Julie Fasano, M.D., a practicing breast cancer oncologist at Mount Sinai Hospital, to deliver a presentation that was both clinically rich and strategically relevant. Titled “The Future of Cancer Care: Innovation, Access, and the Road Ahead,” the session explored how emerging therapies, technologies and care models are reshaping breast cancer treatment — and how Prime is helping clients and members navigate this transformation. 

Putting members at the center of innovation

For members facing a breast cancer diagnosis, the journey is deeply personal and often overwhelming. Prime’s oncology strategy is designed to support them holistically – offering timely access to effective therapies, minimizing treatment delays, and addressing broader challenges like fertility preservation, mental health, and affordability. 

Prime’s oncology team, led by board-certified oncology clinical pharmacists, brings deep expertise to the table and strengthens its impact by partnering with practicing oncology clinicians to ensure real-world relevance and clinical alignment. As Abby Kim shared during the Specialty Summit, “That’s what I love about this partnership — having a practicing oncologist like Dr. Fasano brings real-world clinical experience to our strategy. It ensures that Prime isn’t just following the data — we’re aligning with how care is actually delivered with the patient in mind.” 

As an industry leader in oncology strategy, Prime is not only responding to today’s challenges but actively shaping what comes next. With a deep understanding of clinical trends and a commitment to equitable, member-centered care, Prime is helping clients and providers navigate a rapidly evolving cancer landscape. From detection to treatment, Prime is translating innovation into impact through: 

• Artificial intelligence (AI)-powered mammography, one of the most promising advancements in early detection, with studies showing a 20–30% increase in breast cancer identification. But its potential can only be realized if access is equitable. Prime is working to ensure that emerging technologies like AI-assisted screening are integrated into benefit designs in ways that reduce disparities and improve outcomes for all members. 

• Antibody-drug conjugates (ADCs), which are moving into earlier lines of therapy, including first-line metastatic breast cancer. Prime’s clinical experts evaluate ADCs not just by efficacy, but by side effect profiles — ensuring that therapy choices align with each member’s unique needs and tolerability. This personalized approach helps optimize outcomes while managing cost and complexity. 

• Liquid biopsy and genomic profiling, which are transforming how breast cancer is treated at the molecular level. Prime is closely monitoring the expanding landscape of targeted therapies, including oral selective estrogen receptor degraders (SERDs) and emerging drug classes like proteolysis targeting chimeras (PROTACs). By staying ahead of these innovations, Prime helps members access precision therapies faster — and helps clients prepare for the evolving cost dynamics of personalized medicine. 

As Dr. Julie Fasano shared during the Specialty Summit presentation, “We’re seeing an abundance of new therapies — oral SERDs, PROTACs, ADCs  and Prime is right there, helping translate clinical complexity into actionable strategy. That is what makes them a true leader in oncology.” 

Innovation that delivers value

Prime’s oncology vision is built on a foundation of clinical excellence, strategic foresight, and compassionate care. By staying ahead of emerging therapies and technologies, Prime helps clients: 

• Manage the cost and complexity of high-impact cancer therapies across both pharmacy and medical pharmacy, using an integrated lens to ensure alignment between benefit structures, clinical pathways, and real-world care delivery. 

• Adapt benefit structures to support early detection and personalized treatment. 

• Ensure equitable access to care across diverse member populations. 

• Support providers with timely data, education, and collaboration. 

• Streamline cancer treatment through a member-centric coordinated care solution that supports lower costs to members and promotes improved adherence.  

As we honor Breast Cancer Awareness Month, Prime reaffirms its commitment to advancing cancer care — not just through innovation, but through action that improves lives. 

To learn more about Prime’s oncology strategy and emerging trends in cancer care, read the latest Oncology Insights column.